Log In
Print this Print this

Daliresp, Daxas, roflumilast (APTA-2217)

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionNon-steroidal phosphodiesterase-4 (PDE-4) inhibitor
Molecular Target Phosphodiesterase-4 (PDE-4)
Mechanism of ActionPhosphodiesterase-4 (PDE-4) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat chronic obstructive pulmonary disease (COPD); Treat symptomatic chronic obstructive pulmonary disease (COPD)
Regulatory Designation
Partner Allergan plc; Merck & Co. Inc.; Mitsubishi Tanabe Pharma Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today